MedPath

Radiation-Dose-Lowering Effect of Landiolol Hydrochloride in Coronary Angiography Using Computed Tomography (DELIGHT): A Prospective Multicenter Study

Not Applicable
Conditions
Ischemic Heart Disease
Registration Number
JPRN-UMIN000011817
Lead Sponsor
DELIGHT study group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
250
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with an implantable cardiac pacemaker or an implantable cardioverter-defibrillator 2)Patients who was previously treated with coronary artery bypass grafting 3)Patients with cardiomyopathy 4)Patients with a valve disease 5)Patients with an advanced bradycardia (heart rate less than 50 bpm) 6)Patients with blood pressure less than 110 mmHg at the time into the CT room 7)Patients with atrial fibrillation or premature beat, and expected them during the CTA 8)Patients with contraindication of landiolol hydrochloride 9)Patients with contraindication of nonionic contrast media 10)Patients with relative contraindication of nonionic contrast media and examination doctor judged to be unsuitable for incorporating 11)Patients who had severe allergy experience 12)Patients under pregnancy and breast-feeding and with the possibility of pregnancy, or the patient who wishes to become pregnant during examination period 13)Patients who examination doctor judged to be unsuitable for incorporating because of another reason

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
We compare exposed dose at CT angiography and the estimated exposure dose by the heart rate just before medication.
Secondary Outcome Measures
NameTimeMethod
1) exposed dose at CCTA 2) ratio of the patients who could use prospective gating mode at CT angiograph 3) heart rate, blood pressure 4) assessability of the CCTA 5) adverse events, side effect
© Copyright 2025. All Rights Reserved by MedPath